Besides, FRAS1, FREM1 and FREM2 mRNA and protein expressions were correlated with the clinicopathological characteristics (pathological stage, grade and tumor metastasis status) of the patients with KIRC. This evidence concerns the gene FRAS1 and neoplasm.